NEXMED INC (WKN: 914164 / NEXM) / Nasdaq
Seite 4 von 4 Neuester Beitrag: 14.10.11 18:20 | ||||
| Eröffnet am: | 12.01.09 20:23 | von: 0815ax | Anzahl Beiträge: | 92 |
| Neuester Beitrag: | 14.10.11 18:20 | von: 0815ax | Leser gesamt: | 23.837 |
| Forum: | Hot-Stocks | Leser heute: | 6 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | > | ||||
Optionen
| Boardmail an "dr.soldberg" |
Wertpapier: Seelos Therapeutics Inc |
hoffe das hier keiner long ist :(
Optionen
| Boardmail an "dr.soldberg" |
Wertpapier: Seelos Therapeutics Inc |
*
San Diego -(BUSINESS WIRE) - NexMed, Inc. (Nasdaq: NEXM), eine Spezialität CRO mit einer Pipeline von Produkten auf der Basis NexACT® Technologie, gab heute bekannt, dass Ergebnisse aus einer vorklinischen Studie signifikante Verbesserung bei der Bereitstellung und zeigte Halbwertszeit von A6, ein proprietäres peptide Behandlung für Eierstockkrebs derzeit in Phase 2 der Entwicklung von Angstrom Pharmaceuticals. Insbesondere die Einbeziehung der NexACT® konnte die Dosis von A6 bis um die Hälfte gekürzt werden, oder von zweimal täglich, einmal pro Tag subkutan geliefert, während der Erzielung der gleichen Grad der Wirksamkeit in der Maus Lungenmetastasen Modell.
Bassam Damaj, Ph.D., President und Chief Executive Officer von NexMed, erklärte: "Diese neuen Erkenntnisse, unter Einbeziehung der NexACT A6-peptide Formulierung, korrelieren mit der Halbwertszeit und Lieferung Profil der A6 Verbindung aus früheren Studien Angstrom's mit dem höheren Dosis. Die positiven Ergebnisse bieten Ångstrom das Potenzial, klinisch testen Sie die NexACT A6-Peptid bei sehr viel höheren Dosen unter Beibehaltung kontinuierliche Berichterstattung über die beabsichtigte therapeutische Ziel bei menschlichen Patienten. "Dr. Damaj fügte hinzu:" Diese Studie wurde NexMed erste Eintrag in das subkutane Lieferung von Peptid-Medikamenten, und die Ergebnisse weiter bestätigt, das Depot-Effekt der NexACT® Technologie, die wir in unseren Studien mit subkutaner Lieferung Insulin und Taxol gesehen hatte. "
Malcolm Finlayson, Ph.D., President und Chief Executive Officer von Ångstrom bemerkte: "Unsere Beziehung mit NexMed weiterhin in einem schnellen und Erfolg versprechenden Weg zu entwickeln. Diese neuen Daten ist sehr spannend und rechtfertigt weitere Untersuchungen, um die Möglichkeit, die Lizenz zu unterstützen NexACT® Technologie für klinische Versuche am Menschen. "
Über Ångstrom Pharmaceuticals und A6.
Mit Sitz in San Diego, CA, Ångström ist die Entwicklung einer neuen Klasse von Medikamenten, die an CD44 für die Behandlung von Erkrankungen, bei denen die Zellmigration, Invasion und Metastasierung. Die Ergebnisse einer abgeschlossenen Phase 1a Sicherheit klinischen Studie zeigte auf A6 gab es keine systemischen Medikamenten-Nebenwirkungen bei gesunden Probanden. Ångstrom hat sich auch erfolgreich eine Phase-1b-Studie zur Evaluierung der klinischen A6 bei Frauen mit fortgeschrittenem Krebs gynäkologischen abgeschlossen und eine klinische Phase-2-Studie zur Evaluierung A6 bei Frauen mit asymptomatischer CA125 Progression von epithelialen Ovarialkarzinom nach einer Erstlinien-Chemotherapie. Die Behandlungen wurden gut vertragen und mehr als 40% der Patienten permanent dosiert mit A6 erlebt eine Stabilisierung der Erkrankung. Für weitere Informationen gehen Sie zu www.angstrominc.com/
Über NexMed, Inc.
NexMed ist die größte Spezialität CRO Sitz in San Diego, CA und ist eine der branchenweit am meisten erfahrene CROs für die in vitro und in vivo Pharmakologie Dienstleistungen und Forschungsarbeiten Modelle. Ziel des Unternehmens ist es, die Einnahmen aus dem Wachstum seiner Discovery Vorklinische CRO Geschäft zu generieren, während aggressiv versucht, ihre proprietären NexACT ® Drug-Delivery-Technologie durch Out-Lizenzvereinbarungen mit monetize Pharma-und Biotechnologieunternehmen weltweit. Gleichzeitig ist NexMed aktiv Partnern für ihre NexACT® -Basierten Therapien für Onychomykose, Psoriasis, sexuelle Funktionsstörungen sowie Krebs. Für weitere Informationen über NexMed und ihre Tochtergesellschaften, besuchen Sie die folgenden Websites: http://www.nexmed.com oder http://www.bio-quant.com.
Forward-Looking Statement Safe Harbor für NexMed
Aussagen im Sinne des Private Securities Litigation Reform Act: Mit Ausnahme der historischen Informationen in dieser Pressemitteilung enthalten sind, die hier beschriebenen Inhalte enthalten vorausschauende Aussagen, die Risiken und Unsicherheiten, die einzeln oder gegenseitig beeinflussen könnten, die Dinge hier für eine Vielzahl von beschriebenen Gründen einbeziehen , die außerhalb des Einflussbereichs des Unternehmens, einschließlich, aber nicht ihre Fähigkeit begrenzt, aus der Lizenz-NexACT® Technologie, einschließlich der zu Angstrom, oder die NexACT® -Basierten Produkten in der Entwicklung. Darüber hinaus kann der vorklinischen Ergebnisse der Studie mit Tiermodellen menschlicher Erkrankungen nicht notwendigerweise indikativ für die Ergebnisse, die aus späteren klinischen Studien beim Menschen erwartet werden konnten.
Kontakte:
NexMed, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development NexMed, Inc.
(858) 926-5811
ecox@nexmed.com
NexMed Investor Relations
Paula Schwartz
NexMed, Inc. Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
Ångstrom:
Malcolm Finlayson, Ph.D., President und CEO
Angstrom Pharmaceuticals, Inc.
(858) 314-2356
mfinlayson@angstrominc.com
http://www.nexmed.com/press_04282010.html
Optionen
| Boardmail an "dr.soldberg" |
Wertpapier: Seelos Therapeutics Inc |
Optionen
| Boardmail an "dr.soldberg" |
Wertpapier: Seelos Therapeutics Inc |
Date : 04/28/2010 @ 6:47PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/...pid=nmona&article=42577837&symbol=NEXM
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.
Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, “These new findings, incorporating the NexACT-A6 peptide formulation, correlate with the half life and delivery profile of the Å6 compound from Angstrom’s previous studies using the higher dose. The positive results offer Ångstrom the potential to clinically test the NexACT-Å6 peptide at much higher doses while maintaining continuous coverage of the intended therapeutic target in human patients.” Dr. Damaj further added, “This study was NexMed’s first entry into the subcutaneous delivery of peptide drugs, and the results further confirmed the depot-like effect of the NexACT® technology which we had seen in our subcutaneous delivery studies with insulin and taxol.”
Malcolm Finlayson, Ph.D., President and Chief Executive Officer of Ångstrom noted, “Our relationship with NexMed continues to evolve in a fast and promising way. This new data is very exciting and warrants further investigation to support the opportunity to license the NexACT® technology for human clinical trials.”
About Ångstrom Pharmaceuticals and Å6
Based in San Diego, CA, Ångstrom is developing a new class of drugs targeting CD44 for the treatment of diseases involving cell migration, invasion, and metastasis. Results from a completed Phase 1a safety clinical trial on Å6 showed there were no systemic drug-related adverse events in healthy volunteers. Ångstrom has also successfully completed a Phase 1b clinical trial evaluating Å6 in women with advanced gynecologic cancer, and a Phase 2 clinical trial evaluating Å6 in women with asymptomatic CA125 progression of epithelial ovarian cancer after first-line chemotherapy. Treatments were well tolerated and more than 40% of the patients dosed continuously with Å6 experienced disease stabilization. For further information, go to www.angstrominc.com.
About NexMed
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT®-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Forward-Looking Statement Safe Harbor for NexMed
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to out-license the NexACT® technology, including to Angstrom, or the NexACT®-based products under development. Additionally, pre-clinical study results involving animal models of human disease may not be indicative of the results that could be expected from subsequent clinical trials in humans.
Optionen
| Boardmail an "dr.soldberg" |
Wertpapier: Seelos Therapeutics Inc |
http://www.finanznachrichten.de/...wance-for-nexact-in-canada-004.htm
NexMed Announces Patent Allowance for NexACT® in Canada
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Canadian Patent Office has issued a Notice of Allowance for NexMed's patent application entitled, "Crystalline Salts of Dodecyl 2-(N,N-Dimethylamino)-Propionate." This patent, when issued, will provide Canadian patent protection to May 2020, and is one in a series of patents and pending applications that NexMed owns on the NexACT technology and NexACT-based products under development.
Commenting on today's news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "The Company has a strong intellectual property position. In addition to the allowance in Canada, we have corresponding coverage and protection for our NexACT technology in the U.S. and other major markets. As we pursue our growth goals, we are aggressively seeking to expand the patent coverage for NexACT and to protect its potential for delivering new classes of drugs and/or via new routes of administration such as oral or subcutaneous delivery."
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to obtain and/or enforce patent coverage in major markets.
Contacts:
NexMed Contacts:
NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
© 2010 Business Wire
06.05.2010 22:51
NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT® technology, today announced the appointments of Jack A. Reynolds, Ph.D and Daniel R. Salomon, M.D., to its newly formed Scientific Advisory Board (SAB), expanding the SAB to four members.
Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, noted, "We are delighted to welcome Jack and Dan to our SAB. Our ability to recruit such key leaders in the scientific and medical industries is a testament to the strength of our technology and product pipeline. Both Jack and Dan are distinguished leaders in their respective fields. We look forward to benefiting from their guidance going forward."
Dr. Reynolds is currently Principal of JA Reynolds&Associates and General Managing Partner of Pharma Capital Partners, a private equity fund focused on the development of early-stage pharmaceutical assets. Dr. Reynolds spent a total of almost 18 years with the Pfizer Global Research and Development division, and over 30 years in the pharmaceutical industry. Until August 2006, he was Senior Vice President of Research and Development and Worldwide Head of Safety Sciences and Comparative Medicine. During his lengthy career, Dr. Reynolds has held leadership positions of increasing responsibility at Bristol-Myers Squibb, Bayer and Pfizer. He was also the Founding Director of the Center for Molecular Safety Sciences, a joint collaboration between the non-profit Hamner Center for Molecular Safety Sciences, Duke University and the University of North Carolina.
Dr. Salomon is currently medical director of the Center for Organ and Cell Transplantation for Scripps Health at Scripps Green Hospital and is an associate professor in the department of molecular and experimental medicine at The Scripps Research Institute. He currently serves as Chairman of the Tissue Engineering Committee for the American Society of Gene and Cell Therapy (ASGCT). Dr. Salomon's research interests include; the investigation of how molecular mechanisms driving immune cell activation and tissue injury are regulated at the gene transcriptional and proteomic level and mapping molecular networks that relate to clinical outcomes in cell and organ transplantation. Dr. Salomon previously held the position of chair of the U.S. Food and Drug Administration's Biological Response Modifiers Advisory Committee and has served on multiple NIH study sections and special emphasis panels for over 15 years.
About NexMed:
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed has embarked on a partnering program to pair the NexACT delivery technology with drugs and drug candidates marketed and being developed by others, including NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information, go to www.nexmed.com and www.bio-quant.com.
Contacts:
NexMed, Inc.
Edward Cox, V.P. Investor Relations
858-926-5811
ecox@nexmed.com
or
Rx Communications Group, LLC
Paula Schwartz, 917-322-1216
pschwartz@rxir.com
© 2010 Business Wire
könntes du in kurzen worten mal sagen was es neues giebt
jetzt schon mal danke uwe
www.stockhouse.com/News/USReleasesDetail.aspx
NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT(R) Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously NexMed Inc NEXM | 5/10/2010 5:19:02 PM SAN DIEGO, May 10, 2010 (BUSINESS WIRE) -- NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT(R) technology, today announced data from a pre-clinical study examining the subcutaneous delivery of rituximab, the first FDA-approved therapeutic antibody for the treatment of cancer in the United States. The study results showed that animals receiving subcutaneous injections of rituximab, incorporated with NexACT, demonstrated a 46% enhancement in bioavailability over rituximab, alone. Rituximab is a cancer medication that interferes with the development of cancer cells, slowing their growth and spread in the body. Delivered via intravenous infusion, rituximab is the active drug in Rituxan(R), currently marketed by Genentech and Biogen IDEC, and prescribed to treat Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA). Commenting on today's news, Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, stated, "The ability of the NexACT technology to successfully deliver rituximab subcutaneously in a pre-clinical setting may open the door to improving the delivery of other therapeutic antibodies, which the Company is in the process of studying. The use of human or humanized monoclonal antibodies, therapeutically, was a major breakthrough in the field of medicine. If the NexACT technology can ultimately be shown to lower the amount of antibody administered while improving the route of delivery and minimizing side effects, NexACT could potentially revolutionize the use of these drugs in the future. We look forward to advancing our work in this area and to the further studies that will be needed to validate these results in humans." About NexMed, Inc. NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com. Rituxan(R) is a registered trademark of Biogen IDEC. Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to obtain and/or NexMed's ability to pursue its development strategy and the ability to replicate results from its preclinical research with the NexACT technology in later human clinical studies.
http://www.finanznachrichten.de/...anadian-filing-for-vitaros-004.htm
NexMed Provides Update on Canadian Filing for Vitaros®
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today provided an update on the status of its New Drug Submission ("NDS") with Health Canada for Vitaros®, the Company's topical treatment for erectile dysfunction.
NexMed management has been advised that Health Canada is continuing to review its response for acceptance, and the Company expects to hear from the agency within the next 30 days. An acceptance of the response by Health Canada will trigger a new, 150-day review cycle by the NDS reviewers for a final approval or rejection of the marketing application.
On April 23, 2010, NexMed reported that it had received delivery confirmation of its response to the CMC (Chemistry, Manufacturing and Controls) concerns previously raised by Health Canada (the "Response") related to its New Drug Submission for Vitaros, which was filed in February 2008. The delivery confirmation provided Health Canada with a 45-day screening for acceptance process of the Response by their Regulatory Project Management group, or until approximately June 4, 2010.
Management of NexMed also stated today that the Company is not currently selling shares of its common stock pursuant to the agreement with Brinson Patrick Securities Corporation. Further information concerning the agreement with Brinson is available pursuant to the Company's Form 10Q filed on May 13, 2010.
About NexMed, Inc.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT® drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.
Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company. For example, and without limitation, there can be no assurance that Health Canada will accept the Company's response for review or approve Vitaros for sale in Canada.
Contacts:
NexMed, Inc.
Ed Cox, 858-926-5811
V.P. Investor Relations
ecox@nexmed.com
or
NexMed Investor Relations
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
pschwartz@rxir.com
© 2010 Business Wire
15.06.2010 15:25
NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequvalent to Talconex®
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.
NexMed conducted two pre-clinical studies on its NexACT-based topical psoriasis treatment. The first efficacy study using a cadaver skin model showed that the NexACT-based formulation of the two active drugs delivered the same level of drugs (measured in ug/cm2/hour) as compared to the commercial Talconex® product. In a second efficacy study, using the DNFB induced allergic contact dermatitis (ACD) pig model, results showed that the NexACT-based formulation significantly lowered the clinical inflammation and erythema score in sick animals. The DNFB induced ACD pig model is the standard pre-clinical model for testing efficacy of calcipotriene-based drugs for psoriasis treatments under development.
Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, "We have a competitive psoriasis treatment under development. Our NexACT-based formulation is novel and does not infringe on the marketed topical treatments. Our data, though early stage, shows bioequivalency to Talconex®, and further supports the versatility of the NexACT technology and its applicability to a broad range of disease states. We look forward to commencing partnering discussions for continued development of this product candidate."
(...weiter siehe LINK)
Name Change to Apricus Biosciences - ( APRI )
NexMed, Inc. Announces Results of Special Meeting of Stockholders, Including Name Change to Apricus Biosciences
Date : 09/10/2010 @ 4:31PM
Source : Business Wire
Stock : NexMed, Inc. (NEXM)
http://ih.advfn.com/...pid=nmona&article=44327838&symbol=NEXM
NexMed, Inc. (Nasdaq:NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced the results of its Special Meeting of Stockholders, held today, Friday, September 10, 2010.
At the Special Meeting, the Stockholders of the Company approved, by an affirmative majority vote, to change the name of the Company from NexMed, Inc. to Apricus Biosciences, Inc. (“Apricus Bio”), effective September 10, 2010. The name change was brought on to reflect the broader focus of the Company’s development programs. The Company’s common stock will commence trading under the symbol, NASDAQ: APRI, effective at the open of the market on Tuesday, September 14, 2010.
Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, commented, “Beginning with the acquisition of Bio-Quant by NexMed in late 2009, we have undertaken a number of positive changes that are expected to reshape the Company over the long-term. In particular, we have expanded our product pipeline, re-energized the development of the NexACT technology as a drug delivery platform and have begun active licensing efforts for both proprietary programs, as well as third party programs enhanced with the NexACT technology. Additionally, we have leveraged Bio-Quant’s CRO capabilities to help advance new applications for NexACT. The rebranding of the Company at this time is part of our broader effort to alert potential development partners and the investment community of our new business model.”
In connection with the Company’s name change, management expects to launch its new website, http://www.apricusbio.com on Tuesday, September 14, 2010.
In addition, the Stockholders approved, by an affirmative majority vote, to increase the number of shares of Common Stock authorized for issuance by the Company from 18,000,000 shares to 75,000,000 shares.
About Apricus Biosciences
Backed by a solid, revenue generating CRO business, Bio-Quant, Inc., and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on the Company and its subsidiaries, visit http://www.nexmed.com.